Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders

2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Objectives of Secondary Research
2.1.1.2 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Breakdown of Primaries (Supply- and Demand-Side Participants)
2.1.2.2 Key Objectives of Primary Research
2.2 Market Estimation Methodology
2.2.1 Global Market Estimation
2.2.1.1 Product Revenue Analysis (Bottom-Up Approach)
2.2.1.2 Revenue Share Analysis of Regeneron Pharmaceuticals, Inc.
2.2.1.3 Repository Analysis
2.2.1.4 Primary Interviews
2.2.2 Insights of Primary Experts
2.2.3 Segmental Market Size Estimation (Bottom-Up Approach)
2.3 Market Growth Rate Projections
2.4 Data Triangulation
2.5 Study Assumptions
2.6 Research Limitations
2.7 Risk Analysis

4.1 Ophthalmology Drugs Market Overview
4.2 North America: Ophthalmology Drugs Market, by Molecule
4.3 Ophthalmology Drugs Market Share, by End-user, 2024
4.4 Ophthalmology Drugs Market: Geographic Growth Opportunities

5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Aging Population and Growing Prevalence of Vision Disorders
5.2.1.2 Strong Drug Pipeline and Growing Innovation Efforts
5.2.1.3 Increasing Investments and Strategic Collaborations
5.2.1.4 Improved Reimbursement Policies
5.2.2 Restraints
5.2.2.1 Off-Label Drug Use for Various Indications
5.2.3 Opportunities
5.2.3.1 Shifting Focus on New Drug Modalities
5.2.3.2 Expansion into Emerging Markets
5.2.3.3 High Unmet Needs
5.2.4 Challenges
5.2.4.1 Frequent and Inconvenient Intravitreal Injections Leading to Patient Non-Adherence to Treatment
5.3 Technology Analysis
5.3.1 Key Technologies
5.3.1.1 Hybridoma Technology
5.3.1.2 Recombinant Dna Technology
5.3.1.3 Antibody Engineering
5.3.1.4 Gene Therapy
5.3.1.5 Nanoformulations
5.3.2 Adjacent Technologies
5.3.2.1 Optogenetic Technology
5.3.2.2 Drug-Release Technologies
5.3.2.3 Ocular Implant Technologies
5.3.3 Complementary Technologies
5.3.3.1 3D Printing and Bioprinting
5.3.3.2 Ocular Imaging Technologies
5.4 Trends/Disruptions Impacting Customers’ Businesses
5.5 Pricing Analysis
5.5.1 Indicative Pricing of Ophthalmology Drugs, by Molecule, 2024
5.5.2 Indicative Pricing of Ophthalmology Drugs, by Country, 2024
5.5.3 Indicative Pricing of Ophthalmology Drugs, by Key Player, 2024
5.6 Value Chain Analysis
5.7 Ecosystem Analysis
5.7.1 Ophthalmology Drugs Market: Role of Raw Material Suppliers
5.7.2 Ophthalmology Drugs Market: Role of Product Providers and Phase Iii Pipeline Product Companies
5.7.3 Ophthalmology Drugs Market: Role of End-users
5.7.4 Ophthalmology Drugs Market: Role of Regulatory Authorities
5.8 Patent Analysis
5.9 Regulatory Analysis
5.9.1 Regulatory Landscape
5.9.1.1 Us
5.9.1.2 Europe
5.9.1.3 Emerging Markets
5.9.2 Regulatory Bodies, Government Agencies, and Other Organizations
5.10 Porter's Five Forces Analysis
5.10.1 Intensity of Competitive Rivalry
5.10.2 Bargaining Power of Suppliers
5.10.3 Bargaining Power of Buyers
5.10.4 Threat of Substitutes
5.10.5 Threat of New Entrants
5.11 Key Conferences & Events, 2025-2026
5.12 Reimbursement Scenario
5.13 Key Stakeholders & Buying Criteria
5.13.1 Buying Criteria for Ophthalmology Drugs
5.14 Investment & Funding Scenario
5.15 Pipeline Analysis
5.16 Impact of Artificial Intelligence on Ophthalmology Drugs Market
5.16.1 Challenges in Drug Discovery
5.16.2 Impact of Ai on Discovery of Ophthalmology Drugs
5.17 Impact of 2025 Us Tariffs on Ophthalmology Drugs Market
5.17.1 Key Tariff Rates
5.17.2 Price Impact Analysis
5.17.3 Key Impact on Various Regions
5.17.3.1 Us
5.17.3.2 Europe
5.17.3.3 Apac
5.17.4 Manufacturing Industry Impact
5.17.4.1 Ophthalmology Drug Manufacturers

6.1 Introduction
6.2 Aflibercept
6.2.1 High Efficiency of Aflibercept in Treating Retinal Diseases to Drive Market Growth
6.3 Faricimab
6.3.1 Growing Adoption and Positive Outcomes of Studies to Support Market Growth
6.4 Ranibizumab
6.4.1 Clinical Efficacy of Ranibizumab to Drive Adoption
6.5 Other Molecules

7.1 Introduction
7.2 Monoclonal Antibodies & Fusion Proteins
7.2.1 Growing Focus on Developing New Mabs to Drive Market
7.3 Small Molecules
7.3.1 Increasing Investments and Research to Drive Market
7.4 Other Modalities

8.1 Introduction
8.2 Age-Related Macular Degeneration
8.2.1 Wet Age-Related Macular Degeneration
8.2.1.1 Increasing Demand for Effective Therapies to Drive Market
8.2.2 Dry Age-Related Macular Degeneration
8.2.2.1 Large Market Opportunity for Innovation to Drive Growth
8.3 Diabetic Retinopathy (Dr)
8.3.1 Fewer Approved Drugs to Present Market Opportunities
8.4 Diabetic Macular Edema (Dme)
8.4.1 Growing Adoption of Approved Anti-Vegf Drugs for Dme To Drive Market
8.5 Other Indications

9.1 Introduction
9.2 Intravitreal
9.2.1 High Efficacy of Intravitreal Injections in Treatment of Major Retinal Diseases to Drive Market
9.3 Topical
9.3.1 Ease of Use to Drive Demand for Topical Drugs
9.4 Other Routes of Administration

10.1 Introduction
10.2 Hospitals
10.2.1 Growing Collaborations Between Hospitals and Pharmaceutical Companies to Encourage Growth
10.3 Long-Term Care Facilities
10.3.1 Need for Sustained Medical Supervision and Support for Chronic Conditions to Fuel Market
10.4 Specialty Centers
10.4.1 Rising Inclination Toward Personalized Treatment Plans To Accelerate Growth

11.1 Introduction
11.2 North America
11.2.1 Macroeconomic Outlook for North America
11.2.2 Us
11.2.2.1 Rising Investments in Healthcare Research and Development To Support Growth
11.2.3 Canada
11.2.3.1 Rising Government Initiatives to Support Ophthalmology Drugs Research and Increasing Drug Approvals to Support Growth
11.3 Europe
11.3.1 Macroeconomic Outlook for Europe
11.3.2 Germany
11.3.2.1 Rising Focus on Clinical Research to Drive Market
11.3.3 Uk
11.3.3.1 Ongoing Advancements in Technology to Drive Market Growth
11.3.4 France
11.3.4.1 Growing Investments and Government Support to Drive Market Growth
11.3.5 Italy
11.3.5.1 Growing Investments and Research to Support Market
11.3.6 Spain
11.3.6.1 Growing Geriatric Population to Drive Market Growth
11.3.7 Rest of Europe
11.4 Asia-Pacific
11.4.1 Macroeconomic Outlook for Asia-Pacific
11.4.2 China
11.4.2.1 Large Diabetic Population to Boost Market
11.4.3 Japan
11.4.3.1 Growing Aging Population to Intensify Demand for Effective Treatments
11.4.4 India
11.4.4.1 Increasing Diabetic Cases, Government Support, and Growing Availability of Biosimilars to Support Market
11.4.5 Australia
11.4.5.1 Strong Biopharmaceutical Sector to Drive Market Growth
11.4.6 South Korea
11.4.6.1 Strong R&D Pipeline and Increasing Focus on Research to Support Growth
11.4.7 Rest of Asia-Pacific
11.5 Latin America
11.5.1 Macroeconomic Outlook for Latin America
11.5.2 Brazil
11.5.2.1 Significant Rates of Visual Impairment in Region to Drive Demand For Advanced Treatments
11.5.3 Mexico
11.5.3.1 Growing Research Initiatives and Innovations to Support Market Growth
11.5.4 Rest of Latin America
11.6 Middle East
11.6.1 Macroeconomic Outlook for Middle East
11.6.2 Gcc Countries
11.6.2.1 Growing Research Initiatives and Improving Healthcare Infrastructure to Support Growth
11.6.3 Rest of Middle East
11.7 Africa
11.7.1 Growing Focus on Healthcare to Drive Market Growth
11.7.2 Macroeconomic Outlook for Africa

12.1 Introduction
12.2 Key Player Strategies/Right to Win
12.2.1 Overview of Strategies Adopted by Key Players in Ophthalmology Drugs Market
12.3 Revenue Analysis, 2022-2024
12.4 Market Share Analysis, 2024
12.5 Company Evaluation Quadrant: Key Players, 2024
12.5.1 Stars
12.5.2 Emerging Leaders
12.5.3 Pervasive Players
12.5.4 Participants
12.5.5 Company Footprint: Key Players, 2024
12.5.5.1 Company Footprint
12.5.5.2 Region Footprint
12.5.5.3 Molecule Footprint
12.5.5.4 Modality Footprint
12.5.5.5 Indication Footprint
12.6 Company Evaluation Matrix: Start-Ups/Smes, 2024
12.6.1 Progressive Companies
12.6.2 Responsive Companies
12.6.3 Dynamic Companies
12.6.4 Starting Blocks
12.6.5 Competitive Benchmarking: Startups/Smes, 2024
12.6.5.1 Detailed List of Key Startups/Smes
12.6.5.2 Competitive Benchmarking of Startups/Smes
12.7 Company Valuation & Financial Metrics
12.7.1 Valuation of Key Players
12.7.2 Financial Metrics of Key Players
12.8 Brand/Product Comparison
12.9 Competitive Scenario
12.9.1 Product Launches & Approvals
12.9.2 Deals

13.1 Key Players
13.1.1 Regeneron Pharmaceuticals Inc.
13.1.1.1 Business Overview
13.1.1.2 Products Offered
13.1.1.3 Recent Developments
13.1.1.3.1 Product Approvals
13.1.1.4 Analyst's View
13.1.1.4.1 Right to Win
13.1.1.4.2 Strategic Choices
13.1.1.4.3 Weaknesses & Competitive Threats
13.1.2 F. Hoffmann-La Roche Ltd.
13.1.2.1 Business Overview
13.1.2.2 Products Offered
13.1.2.3 Recent Developments
13.1.2.3.1 Product Launches & Approvals
13.1.2.4 Analyst's View
13.1.2.4.1 Right to Win
13.1.2.4.2 Strategic Choices
13.1.2.4.3 Weaknesses & Competitive Threats
13.1.3 Bayer Ag
13.1.3.1 Business Overview
13.1.3.2 Products Offered
13.1.3.3 Recent Developments
13.1.3.3.1 Product Approvals
13.1.3.4 Analyst's View
13.1.3.4.1 Right to Win
13.1.3.4.2 Strategic Choices
13.1.3.4.3 Weaknesses & Competitive Threats
13.1.4 Novartis Ag
13.1.4.1 Business Overview
13.1.4.2 Products Offered
13.1.4.3 Recent Developments
13.1.4.3.1 Product Approvals
13.1.4.3.2 Deals
13.1.4.4 Analyst's View
13.1.4.4.1 Right to Win
13.1.4.4.2 Strategic Choices
13.1.4.4.3 Weaknesses & Competitive Threats
13.1.5 Abbvie
13.1.5.1 Business Overview
13.1.5.2 Products Offered
13.1.6 Apellis Pharmaceuticals
13.1.6.1 Business Overview
13.1.6.2 Products Offered
13.1.6.3 Recent Developments
13.1.6.3.1 Product Approvals
13.1.6.3.2 Deals
13.1.7 Biogen
13.1.7.1 Business Overview
13.1.7.2 Products Offered
13.1.7.3 Recent Developments
13.1.7.3.1 Product Launches & Approvals
13.1.8 Bausch + Lomb
13.1.8.1 Business Overview
13.1.8.2 Products Offered
13.1.8.3 Recent Developments
13.1.8.3.1 Product Launches & Approvals
13.1.9 Astellas Pharma Inc.
13.1.9.1 Business Overview
13.1.9.2 Products Offered
13.1.9.3 Recent Developments
13.1.9.3.1 Product Approvals
13.1.9.3.2 Deals
13.1.10 Formycon Ag
13.1.10.1 Business Overview
13.1.10.2 Products Offered
13.1.10.3 Recent Developments
13.1.10.3.1 Product Launches & Approvals
13.1.10.3.2 Deals
13.1.11 Biocon
13.1.11.1 Business Overview
13.1.11.2 Products Offered
13.1.11.3 Recent Developments
13.1.11.3.1 Product Approvals
13.1.11.3.2 Deals
13.1.12 Sandoz Group Ag
13.1.12.1 Business Overview
13.1.12.2 Products Offered
13.1.12.3 Recent Developments
13.1.12.3.1 Product Approvals
13.1.12.3.2 Deals
13.1.13 Santen Pharmaceutical Co., Ltd.
13.1.13.1 Business Overview
13.1.13.2 Products Offered
13.1.13.3 Recent Developments
13.1.13.3.1 Product Launches
13.1.14 Innovent
13.1.14.1 Business Overview
13.1.14.2 Products Offered
13.1.14.3 Recent Developments
13.1.14.3.1 Product Approvals
13.1.15 Outlook Therapeutics, Inc.
13.1.15.1 Business Overview
13.1.15.2 Products Offered
13.1.15.3 Recent Developments
13.1.15.3.1 Product Approvals
13.1.15.3.2 Deals
13.1.16 Teva Pharmaceutical Industries Ltd.
13.1.16.1 Business Overview
13.1.16.2 Products Offered
13.1.16.3 Recent Developments
13.1.16.3.1 Product Approvals
13.1.16.3.2 Deals
13.2 Other Players (Pipeline Companies)
13.2.1 Ocular Therapeutix, Inc.
13.2.2 Opthea Limited
13.2.3 Kodiak Sciences Inc.
13.2.4 Eyepoint Pharmaceuticals, Inc.
13.2.5 Alvotech
13.2.6 Clearside Biomedical
13.2.7 Shanghai Henlius Biotech, Inc.
13.2.8 Adverum Biotechnologies, Inc.
13.2.9 Remegen
13.2.10 Sparingvision

14.1 Discussion Guide
14.2 Knowledgestore: The Subscription Portal
14.3 Customization Options

Table 1 Impact Analysis of Supply-Side and Demand-Side Factors
Table 2 Ophthalmology Drugs Market: Risk Analysis
Table 3 Ophthalmology Drugs Market: Impact Analysis
Table 4 Indicative Pricing of Ophthalmology Drugs, by Molecule, 2024
Table 5 Indicative Pricing of Ophthalmology Drugs, by Key Player, 2024
Table 6 Ophthalmology Drugs Market: List of Raw Material Suppliers
Table 7 Ophthalmology Drugs Market: List of Product Providers and Phase Iii Pipeline Product Companies
Table 8 Ophthalmology Drugs Market: List of End-users
Table 9 Ophthalmology Drugs Market: List of Regulatory Authorities
Table 10 Ophthalmology Drugs Market: Indicative List of Patents, 2024
Table 11 North America: Regulatory Bodies, Government Agencies, And Other Organizations
Table 12 Europe: Regulatory Bodies, Government Agencies, And Other Organizations
Table 13 Asia-Pacific: Regulatory Bodies, Government Agencies, And Other Organizations
Table 14 Latin America: Regulatory Bodies, Government Agencies, And Other Organizations
Table 15 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 16 Ophthalmology Drugs Market: Porter's Five Forces Analysis
Table 17 Ophthalmology Drugs Market: List of Conferences & Events
Table 18 Influence of Key Stakeholders on Buying Process (%)
Table 19 Buying Criteria for Ophthalmology Drugs, by End-user
Table 20 Ophthalmology Drugs in Clinical Pipeline, Phase Iii (As of April 2025)
Table 21 Us-Adjusted Reciprocal Tariff Rates
Table 22 Exports and Imports, by Region
Table 23 Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 24 Ophthalmology Drugs Market for Aflibercept, by Region, 2023-2030 (USD Million)
Table 25 North America: Ophthalmology Drugs Market for Aflibercept, By Country, 2023-2030 (USD Million)
Table 26 Europe: Ophthalmology Drugs Market for Aflibercept, by Country, 2023-2030 (USD Million)
Table 27 Asia-Pacific: Ophthalmology Drugs Market for Aflibercept, by Country, 2023-2030 (USD Million)
Table 28 Latin America: Ophthalmology Drugs Market for Aflibercept, By Country, 2023-2030 (USD Million)
Table 29 Middle East: Ophthalmology Drugs Market for Aflibercept, By Region, 2023-2030 (USD Million)
Table 30 Ophthalmology Drugs Market for Faricimab, by Region, 2023-2030 (USD Million)
Table 31 North America: Ophthalmology Drugs Market for Faricimab, By Country, 2023-2030 (USD Million)
Table 32 Europe: Ophthalmology Drugs Market for Faricimab, by Country, 2023-2030 (USD Million)
Table 33 Asia-Pacific: Ophthalmology Drugs Market for Faricimab, by Country, 2023-2030 (USD Million)
Table 34 Latin America: Ophthalmology Drugs Market for Faricimab, By Country, 2023-2030 (USD Million)
Table 35 Middle East: Ophthalmology Drugs Market for Faricimab, by Region, 2023-2030 (USD Million)
Table 36 Ophthalmology Drugs Market for Ranibizumab, by Region, 2023-2030 (USD Million)
Table 37 North America: Ophthalmology Drugs Market for Ranibizumab, By Country, 2023-2030 (USD Million)
Table 38 Europe: Ophthalmology Drugs Market for Ranibizumab, by Country, 2023-2030 (USD Million)
Table 39 Asia-Pacific: Ophthalmology Drugs Market for Ranibizumab, By Country, 2023-2030 (USD Million)
Table 40 Latin America: Ophthalmology Drugs Market for Ranibizumab, By Country, 2023-2030 (USD Million)
Table 41 Middle East: Ophthalmology Drugs Market for Ranibizumab, by Region, 2023-2030 (USD Million)
Table 42 Ophthalmology Drugs Market for Other Molecules, by Region, 2023-2030 (USD Million)
Table 43 North America: Ophthalmology Drugs Market for Other Molecules, By Country, 2023-2030 (USD Million)
Table 44 Europe: Ophthalmology Drugs Market for Other Molecules, By Country, 2023-2030 (USD Million)
Table 45 Asia-Pacific: Ophthalmology Drugs Market for Other Molecules, By Country, 2023-2030 (USD Million)
Table 46 Latin America: Ophthalmology Drugs Market for Other Molecules, By Country, 2023-2030 (USD Million)
Table 47 Middle East: Ophthalmology Drugs Market for Other Molecules, By Region, 2023-2030 (USD Million)
Table 48 Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 49 Ophthalmology Drugs Market for Monoclonal Antibodies & Fusion Proteins, by Region, 2023-2030 (USD Million)
Table 50 North America: Ophthalmology Drugs Market for Monoclonal Antibodies & Fusion Proteins, by Country, 2023-2030 (USD Million)
Table 51 Europe: Ophthalmology Drugs Market for Monoclonal Antibodies & Fusion Proteins, by Country, 2023-2030 (USD Million)
Table 52 Asia-Pacific: Ophthalmology Drugs Market for Monoclonal Antibodies & Fusion Proteins, by Country, 2023-2030 (USD Million)
Table 53 Latin America: Ophthalmology Drugs Market for Monoclonal Antibodies & Fusion Proteins, by Country, 2023-2030 (USD Million)
Table 54 Middle East: Ophthalmology Drugs Market for Monoclonal Antibodies & Fusion Proteins, by Region, 2023-2030 (USD Million)
Table 55 Ophthalmology Drugs Market for Small Molecules, by Region, 2023-2030 (USD Million)
Table 56 North America: Ophthalmology Drugs Market for Small Molecules, By Country, 2023-2030 (USD Million)
Table 57 Europe: Ophthalmology Drugs Market for Small Molecules, By Country, 2023-2030 (USD Million)
Table 58 Asia-Pacific: Ophthalmology Drugs Market for Small Molecules, By Country, 2023-2030 (USD Million)
Table 59 Latin America: Ophthalmology Drugs Market for Small Molecules, By Country, 2023-2030 (USD Million)
Table 60 Middle East: Ophthalmology Drugs Market for Small Molecules, By Region, 2023-2030 (USD Million)
Table 61 Ophthalmology Drugs Market for Other Modalities, by Region, 2023-2030 (USD Million)
Table 62 North America: Ophthalmology Drugs Market for Other Modalities, By Country, 2023-2030 (USD Million)
Table 63 Europe: Ophthalmology Drugs Market for Other Modalities, By Country, 2023-2030 (USD Million)
Table 64 Asia-Pacific: Ophthalmology Drugs Market for Other Modalities, By Country, 2023-2030 (USD Million)
Table 65 Latin America: Ophthalmology Drugs Market for Other Modalities, By Country, 2023-2030 (USD Million)
Table 66 Middle East: Ophthalmology Drugs Market for Other Modalities, By Region, 2023-2030 (USD Million)
Table 67 Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 68 Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 69 Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Region, 2023-2030 (USD Million)
Table 70 North America: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 71 Europe: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 72 Asia-Pacific: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 73 Latin America: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 74 Middle East: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Region, 2023-2030 (USD Million)
Table 75 Ophthalmology Drugs Market for Wet Age-Related Macular Degeneration, by Region, 2023-2030 (USD Million)
Table 76 North America: Ophthalmology Drugs Market for Wet Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 77 Europe: Ophthalmology Drugs Market for Wet Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 78 Asia-Pacific: Ophthalmology Drugs Market for Wet Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 79 Latin America: Ophthalmology Drugs Market for Wet Age-Related Macular Degeneration, by Country, 2023-2030 (USD Million)
Table 80 Middle East: Ophthalmology Drugs Market for Wet Age-Related Macular Degeneration, by Region, 2023-2030 (USD Million)
Table 81 Ophthalmology Drugs Market for Dry Age-Related Macular Degeneration, by Region, 2023-2030 (USD Million)
Table 82 Ophthalmology Drugs Market for Diabetic Retinopathy, By Region, 2023-2030 (USD Million)
Table 83 North America: Ophthalmology Drugs Market for Diabetic Retinopathy, by Country, 2023-2030 (USD Million)
Table 84 Europe: Ophthalmology Drugs Market for Diabetic Retinopathy, By Country, 2023-2030 (USD Million)
Table 85 Ophthalmology Drugs Market for Diabetic Macular Edema, by Region, 2023-2030 (USD Million)
Table 86 North America: Ophthalmology Drugs Market for Diabetic Macular Edema, by Country, 2023-2030 (USD Million)
Table 87 Europe: Ophthalmology Drugs Market for Diabetic Macular Edema, By Country, 2023-2030 (USD Million)
Table 88 Asia-Pacific: Ophthalmology Drugs Market for Diabetic Macular Edema, by Country, 2023-2030 (USD Million)
Table 89 Latin America: Ophthalmology Drugs Market for Diabetic Macular Edema, by Country, 2023-2030 (USD Million)
Table 90 Middle East: Ophthalmology Drugs Market for Diabetic Macular Edema, by Region, 2023-2030 (USD Million)
Table 91 Ophthalmology Drugs Market for Other Indications, by Region, 2023-2030 (USD Million)
Table 92 North America: Ophthalmology Drugs Market for Other Indications, by Country, 2023-2030 (USD Million)
Table 93 Europe: Ophthalmology Drugs Market for Other Indications, By Country, 2023-2030 (USD Million)
Table 94 Asia-Pacific: Ophthalmology Drugs Market for Other Indications, By Country, 2023-2030 (USD Million)
Table 95 Latin America: Ophthalmology Drugs Market for Other Indications, By Country, 2023-2030 (USD Million)
Table 96 Middle East: Ophthalmology Drugs Market for Other Indications, By Region, 2023-2030 (USD Million)
Table 97 Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 98 Ophthalmology Drugs Market for Intravitreal Route of Administration, by Region, 2023-2030 (USD Million)
Table 99 North America: Ophthalmology Drugs Market for Intravitreal Route of Administration, by Country, 2023-2030 (USD Million)
Table 100 Europe: Ophthalmology Drugs Market for Intravitreal Route of Administration, by Country, 2023-2030 (USD Million)
Table 101 Asia-Pacific: Ophthalmology Drugs Market for Intravitreal Route of Administration, by Country, 2023-2030 (USD Million)
Table 102 Latin America: Ophthalmology Drugs Market for Intravitreal Route Of Administration, by Country, 2023-2030 (USD Million)
Table 103 Middle East: Ophthalmology Drugs Market for Intravitreal Route of Administration, by Region, 2023-2030 (USD Million)
Table 104 Ophthalmology Drugs Market for Topical Route of Administration, By Region, 2023-2030 (USD Million)
Table 105 North America: Ophthalmology Drugs Market for Topical Route of Administration, by Country, 2023-2030 (USD Million)
Table 106 Europe: Ophthalmology Drugs Market for Topical Route of Administration, by Country, 2023-2030 (USD Million)
Table 107 Asia-Pacific: Ophthalmology Drugs Market for Topical Route Of Administration, by Country, 2023-2030 (USD Million)
Table 108 Latin America: Ophthalmology Drugs Market for Topical Route of Administration, by Country, 2023-2030 (USD Million)
Table 109 Middle East: Ophthalmology Drugs Market for Topical Route Of Administration, by Region, 2023-2030 (USD Million)
Table 110 Ophthalmology Drugs Market for Other Routes of Administration, By Region, 2023-2030 (USD Million)
Table 111 North America: Ophthalmology Drugs Market for Other Routes of Administration, by Country, 2023-2030 (USD Million)
Table 112 Europe: Ophthalmology Drugs Market for Other Routes of Administration, by Country, 2023-2030 (USD Million)
Table 113 Asia-Pacific: Ophthalmology Drugs Market for Other Routes of Administration, by Country, 2023-2030 (USD Million)
Table 114 Latin America: Ophthalmology Drugs Market for Other Routes of Administration, by Country, 2023-2030 (USD Million)
Table 115 Middle East: Ophthalmology Drugs Market for Other Routes of Administration, by Region, 2023-2030 (USD Million)
Table 116 Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 117 Ophthalmology Drugs Market for Hospitals, by Region, 2023-2030 (USD Million)
Table 118 North America: Ophthalmology Drugs Market for Hospitals, By Country, 2023-2030 (USD Million)
Table 119 Europe: Ophthalmology Drugs Market for Hospitals, by Country, 2023-2030 (USD Million)
Table 120 Asia-Pacific: Ophthalmology Drugs Market for Hospitals, by Country, 2023-2030 (USD Million)
Table 121 Latin America: Ophthalmology Drugs Market for Hospitals, By Country, 2023-2030 (USD Million)
Table 122 Middle East: Ophthalmology Drugs Market for Hospitals, by Region, 2023-2030 (USD Million)
Table 123 Ophthalmology Drugs Market for Long-Term Care Facilities, by Region, 2023-2030 (USD Million)
Table 124 North America: Ophthalmology Drugs Market for Long-Term Care Facilities, by Country, 2023-2030 (USD Million)
Table 125 Europe: Ophthalmology Drugs Market for Long-Term Care Facilities, by Country, 2023-2030 (USD Million)
Table 126 Asia-Pacific: Ophthalmology Drugs Market for Long-Term Care Facilities, by Country, 2023-2030 (USD Million)
Table 127 Latin America: Ophthalmology Drugs Market for Long-Term Care Facilities, by Country, 2023-2030 (USD Million)
Table 128 Middle East: Ophthalmology Drugs Market for Long-Term Care Facilities, by Region, 2023-2030 (USD Million)
Table 129 Ophthalmology Drugs Market for Specialty Centers, by Region, 2023-2030 (USD Million)
Table 130 North America: Ophthalmology Drugs Market for Specialty Centers, by Country, 2023-2030 (USD Million)
Table 131 Europe: Ophthalmology Drugs Market for Specialty Centers, By Country, 2023-2030 (USD Million)
Table 132 Asia-Pacific: Ophthalmology Drugs Market for Specialty Centers, By Country, 2023-2030 (USD Million)
Table 133 Latin America: Ophthalmology Drugs Market for Specialty Centers, By Country, 2023-2030 (USD Million)
Table 134 Middle East: Ophthalmology Drugs Market for Specialty Centers, By Region, 2023-2030 (USD Million)
Table 135 Ophthalmology Drugs Market, by Region, 2023-2030 (USD Million)
Table 136 North America: Macroeconomic Indicators
Table 137 North America: Ophthalmology Drugs Market, by Country, 2023-2030 (USD Million)
Table 138 North America: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 139 North America: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 140 North America: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 141 North America: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 142 North America: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 143 North America: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 144 Us: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 145 Us: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 146 Us: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 147 Us: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 148 Us: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 149 Us: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 150 Canada: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 151 Canada: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 152 Canada: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 153 Canada: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 154 Canada: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 155 Canada: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 156 Europe: Macroeconomic Indicators
Table 157 Europe: Ophthalmology Drugs Market, by Country, 2023-2030 (USD Million)
Table 158 Europe: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 159 Europe: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 160 Europe: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 161 Europe: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 162 Europe: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 163 Europe: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 164 Germany: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 165 Germany: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 166 Germany: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 167 Germany: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 168 Germany: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 169 Germany: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 170 Uk: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 171 Uk: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 172 Uk: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 173 Uk: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 174 Uk: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 175 Uk: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 176 France: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 177 France: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 178 France: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 179 France: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 180 France: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 181 France: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 182 Italy: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 183 Italy: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 184 Italy: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 185 Italy: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 186 Italy: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 187 Italy: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 188 Spain: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 189 Spain: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 190 Spain: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 191 Spain: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 192 Spain: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 193 Spain: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 194 Rest of Europe: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 195 Rest of Europe: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 196 Rest of Europe: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 197 Rest of Europe: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 198 Rest of Europe: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 199 Rest of Europe: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 200 Asia-Pacific: Macroeconomic Indicators
Table 201 Asia-Pacific: Ophthalmology Drugs Market, by Country, 2023-2030 (USD Million)
Table 202 Asia-Pacific: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 203 Asia-Pacific: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 204 Asia-Pacific: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 205 Asia-Pacific: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 206 Asia-Pacific: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 207 Asia-Pacific: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 208 China: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 209 China: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 210 China: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 211 China: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 212 China: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 213 China: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 214 Japan: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 215 Japan: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 216 Japan: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 217 Japan: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 218 Japan: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 219 Japan: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 220 India: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 221 India: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 222 India: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 223 India: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 224 India: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 225 India: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 226 Australia: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 227 Australia: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 228 Australia: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 229 Australia: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 230 Australia: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 231 Australia: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 232 South Korea: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 233 South Korea: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 234 South Korea: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 235 South Korea: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 236 South Korea: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 237 South Korea: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)
Table 238 Rest of Asia-Pacific: Ophthalmology Drugs Market, by Molecule, 2023-2030 (USD Million)
Table 239 Rest of Asia-Pacific: Ophthalmology Drugs Market, by Modality, 2023-2030 (USD Million)
Table 240 Rest of Asia-Pacific: Ophthalmology Drugs Market, by Indication, 2023-2030 (USD Million)
Table 241 Rest of Asia-Pacific: Ophthalmology Drugs Market for Age-Related Macular Degeneration, by Type, 2023-2030 (USD Million)
Table 242 Rest of Asia-Pacific: Ophthalmology Drugs Market, by Route of Administration, 2023-2030 (USD Million)
Table 243 Rest of Asia-Pacific: Ophthalmology Drugs Market, by End-user, 2023-2030 (USD Million)

Figure 1 Ophthalmology Drugs Market Segmentation & Regional Scope
Figure 2 Ophthalmology Drugs Market: Research Design
Figure 3 Ophthalmology Drugs Market: Key Data from Secondary Sources
Figure 4 Ophthalmology Drugs Market: Breakdown of Primary Interviews
Figure 5 Ophthalmology Drugs Market Size Estimation (Supply-Side Analysis), 2024
Figure 6 Product Revenue Analysis-Based Estimation: Bottom-Up Approach (2024)
Figure 7 Revenue Share Analysis of Regeneron Pharmaceuticals, Inc. (2024)
Figure 8 Ophthalmology Drugs Market Size Validation from Primary Sources
Figure 9 Ophthalmology Drugs Market: Bottom-Up Approach
Figure 10 Ophthalmology Drugs Market: CAGR Projections
Figure 11 Ophthalmology Drugs Market: Data Triangulation
Figure 12 Ophthalmology Drugs Market, by Molecule, 2025 Vs. 2030 (USD Million)
Figure 13 Ophthalmology Drugs Market, by Modality, 2025 Vs. 2030 (USD Million)
Figure 14 Ophthalmology Drugs Market, by Route of Administration, 2025 Vs. 2030 (USD Million)
Figure 15 Ophthalmology Drugs Market, by Indication, 2025 Vs. 2030 (USD Million)
Figure 16 Ophthalmology Drugs Market, by End-user, 2025 Vs. 2030 (USD Million)
Figure 17 Geographic Analysis: Ophthalmology Drugs Market
Figure 18 Growing Prevalence of Retinal Diseases and Increasing R&D Investments to Drive Market Growth
Figure 19 Aflibercept Accounted for Largest Share of Ophthalmology Drugs Market in North America in 2024
Figure 20 Hospitals to Dominate Market During Forecast Period
Figure 21 North America Likely to be Fastest-Growing Market in Global Ophthalmology Drugs Market During Forecast Period
Figure 22 Ophthalmology Drugs Market: Drivers, Restraints, Opportunities, and Challenges
Figure 23 Trends/Disruptions Impacting Customers’ Businesses
Figure 24 Indicative Pricing of Ophthalmology Drugs, by Country, 2024
Figure 25 Ophthalmology Drugs Market: Value Chain Analysis
Figure 26 Ophthalmology Drugs Market: Ecosystem Analysis
Figure 27 Ophthalmology Drugs Market: Patent Publication Trends, Jurisdiction, and Top Applicant Analysis (January 2014-December 2024)
Figure 28 Ophthalmology Drugs Market: Porter's Five Forces Analysis
Figure 29 Key Stakeholders in Buying Process of Ophthalmology Drugs, by Modality
Figure 30 Key Buying Criteria for End-users
Figure 31 North America: Ophthalmology Drugs Market Snapshot
Figure 32 Europe: Ophthalmology Drugs Market Snapshot
Figure 33 Revenue Analysis of Key Players, 2022-2024 (USD Million)
Figure 34 Market Share Analysis of Key Players, 2024
Figure 35 Ophthalmology Drugs Market: Company Evaluation Matrix (Key Players), 2024
Figure 36 Ophthalmology Drugs Market: Company Footprint
Figure 37 Ophthalmology Drugs Market: Company Evaluation Matrix (Startups/Smes), 2024
Figure 38 Ev/Ebitda of Key Players
Figure 39 Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Players
Figure 40 Ophthalmology Drugs Market: Brand/Product Comparative Analysis
Figure 41 Regeneron Pharmaceuticals Inc.: Company Snapshot (2024)
Figure 42 F. Hoffmann-La Roche Ltd.: Company Snapshot (2024)
Figure 43 Bayer Ag: Company Snapshot (2024)
Figure 44 Novartis Ag: Company Snapshot (2024)
Figure 45 Abbvie: Company Snapshot (2024)
Figure 46 Apellis Pharmaceuticals: Company Snapshot (2024)
Figure 47 Biogen: Company Snapshot (2024)
Figure 48 Bausch + Lomb: Company Snapshot (2024)
Figure 49 Astellas Pharma Inc.: Company Snapshot (2024)
Figure 50 Formycon Ag: Company Snapshot (2024)
Figure 51 Biocon: Company Snapshot (2024)
Figure 52 Sandoz Group Ag: Company Snapshot (2024)
Figure 53 Santen Pharmaceutical Co., Ltd.: Company Snapshot (2024)
Figure 54 Innovent: Company Snapshot (2024)
Figure 55 Teva Pharmaceutical Industries Ltd.: Company Snapshot (2024)